Phasebio Pharmaceuticals Stock Current Asset
PhaseBio Pharmaceuticals fundamentals help investors to digest information that contributes to PhaseBio Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of PhaseBio Pink Sheet. The fundamental analysis module provides a way to measure PhaseBio Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PhaseBio Pharmaceuticals pink sheet.
PhaseBio |
PhaseBio Pharmaceuticals Company Current Asset Analysis
PhaseBio Pharmaceuticals' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
CompetitionIn accordance with the recently published financial statements, PhaseBio Pharmaceuticals has a Current Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
All Next | Launch Module |
PhaseBio Fundamentals
Return On Asset | -1.06 | |||
Operating Margin | (127.39) % | |||
Current Valuation | (1.26 M) | |||
Shares Outstanding | 49.86 M | |||
Shares Owned By Insiders | 6.72 % | |||
Shares Owned By Institutions | 25.02 % | |||
Number Of Shares Shorted | 2.07 M | |||
Price To Book | 26.18 X | |||
Price To Sales | 1.58 X | |||
Revenue | 10.83 M | |||
Gross Profit | (91.28 M) | |||
EBITDA | (126.73 M) | |||
Net Income | (131.07 M) | |||
Cash And Equivalents | 7.8 M | |||
Cash Per Share | 0.16 X | |||
Total Debt | 1.36 M | |||
Current Ratio | 0.47 X | |||
Book Value Per Share | (2.35) X | |||
Cash Flow From Operations | (47.42 M) | |||
Short Ratio | 1.89 X | |||
Target Price | 1.0 | |||
Number Of Employees | 60 | |||
Beta | 2.52 | |||
Market Capitalization | 1.05 M | |||
Total Asset | 60.54 M | |||
Z Score | -6.6 | |||
Net Asset | 60.54 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in PhaseBio Pink Sheet
If you are still planning to invest in PhaseBio Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseBio Pharmaceuticals' history and understand the potential risks before investing.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
CEOs Directory Screen CEOs from public companies around the world | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |